Systemic infections and inflammation affect chronic neurodegeneration

Nature Reviews Immunology

Volumn 7, Issue 2, 2007, Pages 161-167

  Perry, V Hugh ^a   Cunningham, Colm ^a   Holmes, Clive ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PRION PROTEIN;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ASTHMA; BRAIN DEGENERATION; CELL ACTIVATION; CELL STRUCTURE; CYTOKINE PRODUCTION; DELIRIUM; DISEASE EXACERBATION; HUMAN; INFECTION; INFLAMMATION; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; UPPER RESPIRATORY TRACT INFECTION;

AGING; ANIMALS; BRAIN; COMMUNICABLE DISEASES; HUMANS; INFLAMMATION; MICE; MICROGLIA; NEURODEGENERATIVE DISEASES;

EID: 33846585119     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2015     Document Type: Review

References (90)

1. Combrinck, M. I., Perry, V. H. & Cunningham, C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience 112, 7-11 (2002).
2. Cunningham, C., Wilcockson, D. C., Campion, S., Lunnon, K. & Perry, V. H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 25, 9275-9284 (2005).
3. Dantzer, R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur. J. Pharmacol. 500, 399-411 (2004).
4. Tracey, K. J. The inflammatory reflex. Nature 420, 853-859 (2002).
5. Laflamme, N. & Rivest, S. Effects of systemic immunogenic insults and circulating proinflammatory cytokines on the transcription of the inhibitory factor κBα within specific cellular populations of the rat brain. J. Neurochem. 73, 309-321 (1999).
6. Chakravarty, S. & Herkenham, M. Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J. Neurosci. 25, 1788-1796 (2005).
7. Ek, M. et al. Inflammatory response: pathway across the blood-brain barrier. Nature 410, 430-431 (2001).
8. Perry, V. H. & Gordon, S. Macrophages and microglia in the nervous system. Trends Neurosci. 11, 273-277 (1988).
9. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318 (2005).
10. Hoek, R. M. et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290, 1768-1771 (2000).
11. Mott, R. T. et al. Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia 46, 369-379 (2004).
12. Daws, M. R. et al. Pattern recognition by TREM-2: binding of anionic ligands. J. Immunol. 171, 594-599 (2003).
13. Schmid, C. D. et al. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J. Neurochem. 83, 1309-1320 (2002).
14. Kreutzberg, G. W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19, 312-318 (1996).
15. Raivich, G. et al. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res. Brain Res. Rev. 30, 77-105 (1999).
16. Gordon, S. Alternative activation of macrophages. Nature Rev. Immunol. 3, 23-35 (2003).
17. Stout, R. D. et al. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 175, 342-349 (2005).
18. Etminan, M., Gill, S. & Samii, A. Effect of nonsteroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327, 128 (2003).
19. Chen, H. et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 58, 963-967 (2005).
20. Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421 (2000).
21. McGeer, P. L., Itagaki, S., Tago, H. & McGeer, E. G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79, 195-200 (1987).
22. Simard, A. R., Soulet, D., Gowing, G., Julien, J. P. & Rivest, S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489-502 (2006).
23. D'Andrea, M. R., Cole, G. M. & Ard, M. D. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging 25, 675-683 (2004).
24. Combs, C. K., Karlo, J. C., Kao, S. C. & Landreth, G. E. β-Amyloid stimulation of microglia and monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 21, 1179-1188 (2001).
25. Brown, D. R., Schmidt, B. & Kretzschmar, H. A. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 380, 345-347 (1996).
26. Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J. & Landreth, G. E. A cell surface receptor complex for fibrillar β-amyloid mediates microglial activation. J. Neurosci. 23, 2665-2674 (2003).
27. Koenigsknecht, J. & Landreth, G. Microglial phagocytosis of fibrillar β-amyloid through a β1 integrin-dependent mechanism. J. Neurosci. 24, 9838-9846 (2004).
28. Ajmone-Cat, M. A., Nicolini, A. & Minghetti, L. Prolonged exposure of microglia to lipopolysaccharide modifies the intracellular signaling pathways and selectively promotes prostaglandin E2 synthesis. J. Neurochem. 87, 1193-1203 (2003).
29. Griffin, W. S. & Mrak, R. E. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J. Leukoc. Biol. 72, 233-238 (2002).
30. Lim, G. P. et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714 (2000).
31. Lim, G. P. et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22, 983-991 (2001).
32. Quinn, J. et al. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J. Neuroimmunol. 137, 32-41 (2003).
33. Sly, L. M. et al. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. Bull. 56, 581-588 (2001).
34. Wyss-Coray, T. et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl Acad. Sci. USA 99, 10837-10842 (2002).
35. Hensley, K. et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem. 82, 365-374 (2002).
36. Hensley, K. et al. Message and protein-level elevation of tumor necrosis factor α (TNFα) and TNFα-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol. Dis. 14, 74-80 (2003).
37. Nguyen, M. D., Julien, J. P. & Rivest, S. Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1β in neurodegeneration. Ann. Neurol. 50, 630-639 (2001).
38. Depino, A. M. et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci. 18, 2731-2742 (2003).
39. Sriram, K. et al. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16, 1474-1476 (2002).
40. Rousselet, E. et al. Role of TNF-α receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp. Neurol. 177, 183-192 (2002).
41. Leng, A., Mura, A., Feldon, J. & Ferger, B. Tumor necrosis factor-α receptor ablation in a chronic MPTP mouse model of Parkinson's disease. Neurosci. Lett. 375, 107-111 (2005).
42. Brown, A. R. et al. Inducible cytokine gene expression in the brain in the ME7/CV mouse model of scrapie is highly restricted, is at a strikingly low level relative to the degree of gliosis and occurs only late in disease. J. Gen. Virol. 84, 2605-2611 (2003).
43. Cunningham, C., Wilcockson, D. C., Boche, D. & Perry, V. H. Comparison of inflammatory and acutephase responses in the brain and peripheral organs of the ME7 model of prion disease. J. Virol. 79, 5174-5184 (2005).
44. Cunningham, C., Boche, D. & Perry, V. H. Transforming growth factor β1, the dominant cytokine in murine prion disease: influence on inflammatory cytokine synthesis and alteration of vascular extracellular matrix. Neuropathol. Appl. Neurobiol. 28, 107-119 (2002).
45. Felton, L. M. et al. MCP-1 and murine prion disease: Separation of early behavioural dysfunction from overt clinical disease. Neurobiol. Dis. 20, 283-295 (2005).
46. Mabbott, N. A. et al. Tumor necrosis factor α-deficient, but not interleukin-6-deficient, mice resist peripheral infection with scrapie. J. Virol. 74, 3338-3344 (2000).
47. Schultz, J. et al. Role of interleukin-1 in prion disease-associated astrocyte activation. Am. J. Pathol. 165, 671-678 (2004).
48. Bogdan, C., Paik, J., Vodovotz, Y. & Nathan, C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10. J. Biol. Chem. 267, 23301-23308 (1992).
49. McDonald, P. P., Fadok, V. A., Bratton, D. & Henson, P. M. Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-β in macrophages that have ingested apoptotic cells. J. Immunol. 163, 6164-6172 (1999).
50. Schook, L. B., Albrecht, H., Gallay, P. & Jongeneel, C. V. Cytokine regulation of TNF-α mRNA and protein production by unprimed macrophages from C57Bl/6 and NZW mice. J. Leukoc. Biol. 56, 514-520 (1994).
51. Chantry, D., Turner, M., Abney, E. & Feldmann, M. Modulation of cytokine production by transforming growth factor-β. J. Immunol. 142, 4295-4300 (1989).
52. Ye, S. M. & Johnson, R. W. An age-related decline in interleukin-10 may contribute to the increased expression of interleukin-6 in brain of aged mice. Neuroimmunomodulation 9, 183-192 (2001).
53. De Simone, R., Ajmone-Cat, M. A., Carnevale, D. & Minghetti, L. Activation of α7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J. Neuroinflammation 2, 4 (2005).
54. Cunningham, C. et al. Synaptic changes characterize early behavioural changes in the ME7 model of murine prion disease. Eur. J. Neurosci. 17, 2147-2155 (2003).
55. Boche, D., Cunningham, C., Docagne, F., Scott, H. & Perry, V. H. TGFβ1 regulates the inflammatory response during chronic neurodegeneration. Neurobiol. Dis. 22, 638-650 (2006).
56. Thackray, A. M., McKenzie, A. N., Klein, M. A., Lauder, A. & Bujdoso, R. Accelerated prion disease in the absence of interleukin-10. J. Virol. 78, 13697-13707 (2004).
57. DiCarlo, G., Wilcock, D., Henderson, D., Gordon, M. & Morgan, D. Intrahippocampal LPS injections reduce Aβ load in APP + PS1 transgenic mice. Neurobiol. Aging 22, 1007-1012 (2001).
58. Herber, D. L. et al. Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic mice. Exp. Neurol. 190, 245-253 (2004).
59. Wilcock, D. M. et al. Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration. Neurobiol. Dis. 15, 11-20 (2004).
60. Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916-919 (2000).
61. Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
62. Perry, V. H., Newman, T. A. & Cunningham, C. The impact of systemic infection on the progression of neurodegenerative disease. Nature Rev. Neurosci. 4, 103-112 (2003).
63. Godbout, J. P. et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J. 19, 1329-1331 (2005).
64. Perry, V. H., Matyszak, M. K. & Fearn, S. Altered antigen expression of microglia in the aged rodent CNS. Glia 7, 60-67 (1993).
65. Godbout, J. P. & Johnson, R. W. Interleukin-6 in the aging brain. J. Neuroimmunol. 147, 141-144 (2004).
66. Kyrkanides, S., O'Banion, M. K., Whiteley, P. E., Daeschner, J. C. & Olschowka, J. A. Enhanced glial activation and expression of specific CNS inflammation-related molecules in aged versus young rats following cortical stab injury. J. Neuroimmunol. 119, 269-277 (2001).
67. Barrientos, R. M. et al. Peripheral infection and aging interact to impair hippocampal memory consolidation. Neurobiol. Aging 27, 723-732 (2006).
68. Lee, J., Chan, S. L. & Mattson, M. P. Adverse effect of a presenilin-1 mutation in microglia results in enhanced nitric oxide and inflammatory cytokine responses to immune challenge in the brain. Neuromolecular Med. 2, 29-45 (2002).
69. Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N. & LaFerla, F. M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 8843-8853 (2005).
70. Nguyen, M. D., D'Aigle, T., Gowing, G., Julien, J. P. & Rivest, S. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 24, 1340-1349 (2004).
71. McCusker, J., Cole, M., Dendukuri, N., Belzile, E. & Primeau, F. Delirium in older medical inpatients and subsequent cognitive and functional status: a prospective study. Can. Med. Assoc. J.165, 575-583 (2001).
72. Rahkonen, T., Luukkainen-Markkula, R., Paanila, S., Sivenius, J. & Sulkava, R. Delirium episode as a sign of undetected dementia among community dwelling elderly subjects: a 2 year follow up study. J. Neurol. Neurosurg. Psychiatry 69, 519-521 (2000).
73. Fick, D. M., Agostini, J. V. & Inouye, S. K. Delirium superimposed on dementia: a systematic review. J. Am. Geriatr. Soc. 50, 1723-1732 (2002).
74. Dunn, N., Mullee, M., Perry, V. H. & Holmes, C. Association between dementia and infectious disease: evidence from a case-control study. Alzheimer Dis. Assoc. Disord. 19, 91-94 (2005).
75. Engelhart, M. J. et al. Inflammatory proteins in plasma and the risk of dementia: The Rotterdam Study. Arch. Neurol. 61, 668-672 (2004).
76. Tilvis, R. S. et al. Predictors of cognitive decline and mortality of aged people over a 10-year period. J. Gerontol. A 59, 268-274 (2004).
77. Ott, A. et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942 (1999).
78. Andersen, K., Lolk, A., Kragh-Sorensen, P., Petersen, N. E. & Green, A. Depression and the risk of Alzheimer disease. Epidemiology 16, 233-238 (2005).
79. Fleminger, S., Oliver, D. L., Lovestone, S., Rabe-Hesketh, S. & Giora, A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J. Neurol. Neurosurg. Psychiatry 74, 857-862 (2003).
80. Craig, D., Mirakhur, A., Hart, D. J., McIlroy, S. P. & Passmore, A. P. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am. J. Geriatr. Psychiatry 13, 460-468 (2005).
81. Starkstein, S. E., Jorge, R., Mizrahi, R. & Robinson, R. G. A prospective longitudinal study of apathy in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 77, 8-11 (2006).
82. Hope, T., Keene, J., Fairburn, C. G., Jacoby, R. & McShane, R. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study. Br. J. Psychiatry 174, 39-44 (1999).
83. Yip, A. G., Brayne, C. & Matthews, F. E. Risk factors for incident dementia in England and Wales: The Medical Research Council Cognitive Function and Ageing Study. A population-based nested case-control study. Age Ageing 35, 154-160 (2006).
84. Robert, P. H. et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease. A one-year follow-up study. Clin. Neurol. Neurosurg. 108, 733-736 (2006).
85. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 4th edn (American Psychiatric Association, Washington DC, 1994).
86. Clark, C. M. et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch. Neurol. 56, 857-862 (1999).
87. Holmes, C. & Lovestone, S. Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing 32, 200-204 (2003).
88. Holmes, C. et al. Systemic infection, interleukin 1β, and cognitive decline in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74, 788-789. (2003).
89. Hart, B. L. Biological basis of the behavior of sick animals. Neurosci. Biobehav. Rev. 12, 123-137 (1988).
90. Blond, D., Campbell, S. J., Butchart, A. G., Perry, V. H. & Anthony, D. C. Differential induction of interleukin-1β and tumour necrosis factor-α may account for specific patterns of leukocyte recruitment in the brain. Brain Res. 958, 89-99 (2002).